Cervical Cancer — Expert Gynecologic Oncology & Advanced Therapy Access

Cervical cancer is caused by persistent infection with high-risk human papillomavirus (HPV) types, most commonly HPV-16 and HPV-18, which together account for approximately 70% of cases. HPV is a sexually transmitted virus that infects the cervical epithelium; in most women, the immune system clears the infection, but in some, persistent infection leads to pre-cancerous changes (cervical intraepithelial neoplasia, CIN) and eventually invasive cancer. Cervical cancer is largely preventable through HPV vaccination before first sexual exposure (which reduces risk by approximately 90%) and regular cervical screening (Pap smear and HPV co-testing) to detect and treat pre-cancerous changes before they progress.

Early cervical cancer — including pre-invasive CIN — typically causes no symptoms, which is why screening is so important. When invasive cancer develops, the most common first symptoms are: abnormal vaginal bleeding (particularly between periods, after sexual intercourse — called post-coital bleeding — or after menopause), unusual vaginal discharge (watery, bloody, or with an unpleasant odour), and pelvic pain or discomfort. Post-coital bleeding is an especially important warning symptom that requires immediate gynaecological evaluation with colposcopy and cervical biopsy.

Yes — concurrent chemoradiation (external beam radiotherapy with platinum-based chemotherapy) combined with intracavitary brachytherapy is the standard curative treatment for locally advanced cervical cancer (FIGO IB3 and above) and produces comparable — or in some settings superior — cure rates to radical surgery for these stages. Even for some earlier stages, definitive chemoradiation is an alternative to surgery, particularly when surgical risk is high or fertility preservation is not a consideration. For very early microinvasive disease (FIGO IA1), LLETZ excision alone can be curative in selected cases.

Brachytherapy is a form of internal radiotherapy in which radioactive sources are placed directly inside or next to the tumour — in this case, inside the cervix/uterus and vagina — using special applicators. In cervical cancer, high-dose rate (HDR) intracavitary brachytherapy delivers a highly concentrated radiation boost directly to the cervical tumour with much greater precision than external beam radiotherapy, while minimising dose to surrounding organs (bladder, rectum). It is a non-negotiable component of curative chemoradiation for locally advanced cervical cancer — centres that omit brachytherapy due to limited access have significantly inferior outcomes. Modern MRI-guided adaptive brachytherapy achieves local control rates exceeding 90% in selected patients.

Pembrolizumab is an immune checkpoint inhibitor that blocks the PD-1 protein on T-cells, re-activating the immune system's ability to recognise and destroy cancer cells. In cervical cancer, it is approved based on the KEYNOTE-826 trial for patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS ≥1). Adding pembrolizumab to standard platinum-taxane chemotherapy and bevacizumab (anti-VEGF) as first-line treatment produced significantly improved overall survival compared to chemotherapy and bevacizumab alone. PD-L1 CPS testing on the tumour biopsy is required to confirm eligibility.

For carefully selected women with early-stage cervical cancer (FIGO IA2–IB1, tumours ≤2 cm), fertility-sparing surgery called radical trachelectomy — where the cervix is removed but the uterus is preserved — is a recognised surgical option. This procedure maintains the possibility of future pregnancy (though preterm delivery risk is increased). It is only appropriate for small tumours without lymph node involvement, no lymphovascular space invasion, and no distant spread. Radical trachelectomy is performed by specialist gynaecologic oncology surgeons; evaluation requires referral to a centre with expertise in this procedure.

Two major advances have occurred in the management of recurrent or metastatic cervical cancer. First, pembrolizumab in combination with bevacizumab and platinum-taxane chemotherapy (KEYNOTE-826) is now the preferred first-line regimen for PD-L1 CPS ≥1 disease. Second, tisotumab vedotin — an antibody-drug conjugate targeting Tissue Factor — was approved as second-line therapy for recurrent/metastatic cervical cancer after prior chemotherapy (innovaTV 204 trial). Tisotumab vedotin delivers a cytotoxic payload (MMAE) directly to Tissue Factor-expressing cervical cancer cells and has shown meaningful response rates and survival benefit in this setting.

Yes. Cervical cancer has an active clinical trial landscape. Current trials include: KEYNOTE-A18/ENGOT-cx11 (pembrolizumab added to chemoradiation for locally advanced cervical cancer); innovaTV 301 (tisotumab vedotin + pembrolizumab + carboplatin as first-line); HPV E6/E7-targeted TCR-engineered T-cell therapies; therapeutic HPV vaccines; TIL therapy; and PIK3CA and NTRK-targeted precision therapy trials. Patients with recurrent or metastatic cervical cancer — particularly those who have progressed on prior therapy — are especially encouraged to explore trial eligibility. CancerFax can assist in identifying relevant trials and connecting patients with specialist gynaecologic oncology research centres internationally.

Yes. CancerFax provides comprehensive specialist support for cervical cancer patients at all stages of their treatment journey. We review colposcopy and biopsy reports, staging MRI and PET-CT findings, PD-L1 CPS and molecular profiling results, and surgical or radiation treatment histories, then connect patients with specialist gynaecologic oncologists and radiation oncologists — in India, South Korea, Germany, the UAE, and other countries with specialist cervical cancer programmes. We assist with second opinions on surgical versus chemoradiation approaches, fertility preservation evaluation, pembrolizumab and tisotumab vedotin access, clinical trial identification (including TIL and HPV-directed therapies), and comprehensive coordination for international treatment options.